Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users.

Human genomics - 11 Apr 2026

Albawa'neh Areej S, Alqasrawi Mais N, Al-Mahayri Zeina N, Al Dain Marzouka Nour, Dabaghie Lilas, Hamza Dana, Khasawneh Lubna Q, Misra Virendra, Ouda Husam, Ali Bassam R

Abstract excerpt

BACKGROUND: Statins are widely prescribed lipid-lowering agents, but their use is associated with an increased risk of new-onset type 2 diabetes mellitus (NO-T2DM) ranging from 9% to 13%. While genetic variants in 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the pharmacological target of statins, and the solute carrier organic anion transporter family, member 1B1 (SLCO1B1), a key hepatic transporter, have...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Atorvastatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Case-Control Studies

Share to Diabetes Mellitus, Type 2

Share to Haplotypes

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hydroxymethylglutaryl CoA Reductases

Share to Liver-Specific Organic Anion Transporter 1

Source

Open in PubMed Open full text

Identifiers

PMID: 41965920
DOI: 10.1186/s40246-026-00962-7
PMCID: PMC13200291

Genes

HMGCR
SLCO1B1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HMGCR genetic variation and risk of new-onset type 2 diabetes in statin users.PMID 41965920Read ↗

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials.Semantic proximity Read ↗

Genetic insights into statin-associated diabetes risk.Semantic proximity Read ↗

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study.Semantic proximity Read ↗

Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis.Semantic proximity Read ↗

A paucimorphic variant in the HMG-CoA reductase gene is associated with lipid-lowering response to statin treatment in diabetes: a GoDARTS study.Semantic proximity Read ↗

MassARRAY multigene screening combined with LDL-C and sdLDL-C detection for more favorable outcomes in type 2 diabetes mellitus therapy.Semantic proximity Read ↗

A Mendelian Randomization Approach Using 3-HMG-Coenzyme-A Reductase Gene Variation to Evaluate the Association of Statin-Induced Low-Density Lipoprotein Cholesterol Lowering With Noncardiovascular Disease Phenotypes.Semantic proximity Read ↗

Drug targets for lipid modification and risk of type 2 diabetes: a cis-Mendelian randomization study.Semantic proximity Read ↗

Association of HMGCR rs17671591 and rs3761740 with lipidemia and statin response in Uyghurs and Han Chinese.Semantic proximity Read ↗

The Genetic Link Between Diabetes and Atherosclerosis.Semantic proximity Read ↗

Novel polymorphism of the HMGCR gene related to the risk of diabetes in premature triple-vessel disease patients.Semantic proximity Read ↗

Common variant in the HMGA2 gene increases susceptibility to nephropathy in patients with type 2 diabetes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.